19 in stock
PNC-27 10 mg is a chimeric p53-derived research peptide attracting scientific interest for its reported ability to bind membrane-associated HDM2 and promote pore formation and rapid lysis in selected cancer-cell models.
PNC-27 is an experimental chimeric peptide built from amino-acid residues 12–26 of the p53 tumour-suppressor protein. This p53-derived region contains an HDM2-binding domain. Researchers joined it to a membrane-translocating penetratin sequence derived from the Drosophila Antennapedia protein.
The original concept was to carry a p53-derived sequence into cancer cells and interfere with the interaction between p53 and HDM2. Laboratory observations revealed a different and potentially compelling action: intact PNC-27 accumulated with HDM2 in the plasma membrane of several cancer-cell models, followed by pore formation, loss of membrane integrity and rapid necrotic cell death.
This unusual membrane-directed mechanism has generated interest because it differs from conventional apoptosis-inducing compounds. However, the findings remain preclinical and do not establish PNC-27 10 mg as a cancer treatment.
Cell experiments describe membrane disruption and necrotic lysis on a faster timescale than would be expected from gene transcription or classical programmed cell death.
Several studies found stronger cytotoxicity in transformed cells displaying membrane HDM2 than in the matched or related untransformed control cells tested alongside them.
Positive laboratory findings span breast, ovarian, uterine, cervical and leukemia-derived cells, supporting continued study across diverse experimental models.
Microscopy and structural work support a model in which PNC-27 binds the p53-binding region of HDM2 at the cell surface. Multiple complexes may then organize into membrane-spanning pores. The resulting loss of membrane integrity releases intracellular contents and produces necrotic morphology.
| Experimental model | Encouraging observation | Evidence level | Important context |
|---|---|---|---|
| Breast-cell models | Intact peptide accumulated in MCF-7 cancer-cell membranes during lysis, while the untransformed MCF-10-2A cells used as controls remained viable. | In-vitro cell-line study | Selectivity between two laboratory cell lines does not prove universal sparing of normal human tissue. |
| K562 leukemia cells | Researchers reported strong membrane HDM2 expression, peptide co-localization and extensive necrotic killing in a p53-null leukemia cell line. | In-vitro cell-line study | A leukemia cell line is not equivalent to leukemia in a patient or to every blood-cancer subtype. |
| Primary ovarian and uterine cells | Ex-vivo experiments reported cytotoxic responses in primary tumour cells collected from surgical specimens. | Ex-vivo human-cell research | Cells outside the body do not reproduce exposure, distribution, metabolism or whole-body safety. |
| Cervical-cell models | A 2025 study reported killing across three cervical cancer cell lines with limited effect on the normal cervical epithelial cells tested. | In-vitro cell-line study | The reported enhancement with acetoacetate is an early laboratory finding, not a clinical combination protocol. |
| Mitochondrial interaction | Recent microscopy suggests that peptide entering treated cancer cells may also associate with mitochondrial membranes and contribute to disruption. | Mechanistic laboratory research | This is a developing extension of the membrane-pore model and requires independent confirmation. |
The positive laboratory findings around PNC-27 10 mg support several focused lines of investigation:
Selectivity is one of the most encouraging features reported in the PNC-27 literature. In several experiments, transformed cells displaying membrane-associated HDM2 were damaged while the particular untransformed control cells tested alongside them remained viable.
That result supports a valuable research hypothesis, but it does not demonstrate perfect selectivity across every organ, normal cell type or disease state. Cell lines are grown under controlled conditions, and ex-vivo tumour samples do not reproduce whole-body distribution, metabolism, immune responses or off-target exposure.
The most scientifically useful next step is to define which cells display membrane HDM2, whether target density predicts response and how normal tissues behave in rigorous animal studies. This keeps the promising selectivity findings central without treating them as established human safety.
| Feature | PNC-27 | PNC-28 |
|---|---|---|
| p53-derived region | p53 residues 12–26 | Shorter p53 region, residues 17–26 |
| Carrier region | Penetratin sequence | Penetratin sequence |
| Proposed mechanism | Membrane HDM2 binding, pore formation and necrotic lysis | Closely related membrane-pore mechanism |
| Evidence emphasis | Cell-line, primary-cell and mechanistic studies | Includes published pancreatic-tumour mouse work |
Findings involving PNC-28 are informative background for the peptide family, but they should not be presented as direct evidence for PNC-27. The compounds differ in their p53-derived sequence and require product-specific study.
Most published PNC-27 work exposes cultured cell lines or primary tumour cells to measured laboratory concentrations. These experiments are useful for comparing cytotoxicity, membrane disruption and target expression, but they do not establish a dose for a whole organism.
Related animal experiments involving PNC-28 have used model-specific delivery methods. Those data cannot be converted into a human route, dose or schedule for PNC-27. No validated clinical protocol or established therapeutic window has been published for this product.
The 10 mg designation describes the total laboratory quantity in the vial. It is not a dose, cycle length, injection schedule or administration instruction.
No controlled human trials have established the safety, tolerability, distribution, effective exposure or clinical benefit of PNC-27. Laboratory selectivity cannot substitute for toxicology studies across normal organs and tissues.
A published case report described a serious gastrointestinal hemorrhage following experimental PNC-27 use. A single report cannot determine causation or frequency, but it reinforces why cell-culture findings should not be treated as proof of human safety.
Overall, the HDM2-associated pore-forming mechanism and selective effects reported in several experimental systems make PNC-27 10 mg a compelling laboratory research compound. It is not an established cancer therapy and should not replace evidence-based oncology care or clinical-trial participation.
These compounds investigate different biological systems and should not be treated as interchangeable. Combining research compounds does not establish additive, protective or synergistic effects.
Research-use notice: PNC-27 10 mg is presented for laboratory research and analytical discussion only. It is not intended to diagnose, treat, cure or prevent cancer or any other disease, or for human or animal use. This information is not medical advice or an administration guide.
